Chimärer Antigenrezeptor und Car-T-Zellen zur Bindung von Bcma

Details

Veröffentlichungs-Nr.

EP4737481

Anmeldetag

7. Juni 2017

Veröffentlichung

6. Mai 2026

Rechtsraum

EP

IPC

C07K16/28(NOVARTIS AG et al.)

Abstract

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

Anmelder

Firma

Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft

Land

🇩🇪 Deutschland

Fachgebiete